Tyra Biosciences, Inc.
NASDAQ:TYRABiotechnology
-$0.72 today
- Market cap
- $1.35B
- Beta
- 0.75
- P/E (TTM)
- -13.4
- EPS (TTM)
- -$2.12
Volume 0.47M
Average 0.96M
TYRA Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
Tyra Biosciences, Inc.NASDAQ: TYRA
Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026
Selling, general & admin growth accelerates
Q1 FY2026 selling, general & admin of $8.53M rose 23.8% year over year, ahead of the +21.6% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 2.4% from the prior quarter. Over 3 fiscal years it compounded at +23.3% a year.
Context
- Selling, general & admin increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether selling, general & admin reaches the consensus estimate from 7 analysts of $0 (-100.0%) for the fiscal year ending Dec 2026, a slowdown from the +23.8% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $8.53M+2.4% QoQ
- Last fiscal yearDec 2025
- $29.83M+23.8% YoY
- LTMMar 2026
- $31.48M+21.6% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +23.8% | -100.0% | -123.8 pp |
| 1 year | +23.8% | -100.0% | -123.8 pp |
| 3-year CAGR | +23.3% | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 29.83M USD
- Year-over-year change
- +23.8%
- 4-year CAGR
- +51.6%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 29.83M | +23.8% |
| FY2024 | 2024-12-31 | 24.1M | +38.3% |
| FY2023 | 2023-12-31 | 17.43M | +9.5% |
| FY2022 | 2022-12-31 | 15.92M | +181.7% |
| FY2021 | 2021-12-31 | 5.65M | — |
Selling, General & Admin vs competitors
How TYRA compares with its peers on the latest reported figures
- TYRA's LTM Mar 2026 selling, general & admin of $31.48M is the 9th highest of the 11 companies compared; the peer median is $40.36M.
- Its year-over-year change of +21.6% is the 6th highest of 11, against a peer median of +22.6%.
- Over three fiscal years its annual growth of +23.3% compares with a peer median of +30.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $158.59M | +32.6% | +68.1% | 93.3% | |
| LTM Mar 2026 | $128.35M | +57.4% | +36.6% | 179.2% | |
| LTM Mar 2026 | $88.42M | +83.1% | +48.1% | 178.3% | |
| LTM Mar 2026 | $52.28M | -5.2% | +10.5% | — | |
| LTM Mar 2026 | $42.56M | -1.1% | +23.3% | 196.9% | |
| LTM Mar 2026 | $38.15M | -27.9% | -12.7% | 24.3% | |
BCAXBicara Therapeutics Inc. Common Stock | LTM Mar 2026 | $35.8M | +56.4% | +68.8% | — |
| LTM Mar 2026 | $33.29M | +12.6% | +9.8% | — | |
| LTM Mar 2026 | $31.48M | +21.6% | +23.3% | — | |
| LTM Mar 2026 | $27.19M | +59.1% | +55.2% | — | |
| LTM Mar 2026 | $26.89M | -3.6% | -3.6% | 95.3% | |
| Peer median (excluding TYRA) | $40.36M | +22.6% | +30.0% | 136.8% | |
Competitors are the stored peer set for TYRA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 20.64M | 43.01M | 62.52M | 80.08M | 102.93M |
| Selling, General & Admin | 5.65M | 15.92M | 17.43M | 24.1M | 29.83M |
| Operating Expenses | 26.29M | 58.93M | 79.95M | 104.18M | 132.76M |
| Depreciation & Amortization | 140K | 296K | 357K | 519K | 546K |
| EBITDA | (26.15M) | (55.03M) | (68.78M) | (85.96M) | (119.4M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (26.29M) | (58.93M) | (79.95M) | (104.18M) | (132.76M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 13K | 3.65M | 10.81M | 17.7M | 12.82M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (6K) | 3.6M | 10.81M | 17.7M | 12.82M |
| Income Before Tax | (26.29M) | (55.33M) | (69.13M) | (86.48M) | (119.95M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (26.29M) | (55.33M) | (69.13M) | (86.48M) | (119.95M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (0.63) | (1.23) | (1.62) | (1.51) | (2.01) |
| EPS (Diluted) | (0.63) | (1.23) | (1.62) | (1.51) | (2.01) |
| Weighted Avg Shares | 41.44M | 41.88M | 42.7M | 57.22M | 59.6M |
| Weighted Avg Shares (Diluted) | 41.44M | 41.88M | 42.7M | 57.22M | 59.6M |
Tyra Biosciences, Inc.
NASDAQ:TYRA
Intrinsic Alpha fair value
Locked
Current Price
$19.61
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.